SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Killestein, J
Right arrow Articles by Van Lier, R A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Killestein, J
Right arrow Articles by Van Lier, R A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease

J Killestein

Department of Neurology, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands, Department of Clinical Viro-Immunology, CLB, PO Box 9092, 1066 CX, Amsterdam, The Netherlands

B F Den Drijver

Department of Neurology, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands

W L Van der Graaff

Department of Neurology, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands

B MJ Uitdehaag

Department of Neurology, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands

C H Polman

Department of Neurology, VU Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands

R AW Van Lier

Department of Clinical Viro-Immunology, CLB, PO Box 9092, 1066 CX, Amsterdam, The Netherlands

Objective: To evaluate the expression of cytokines in both CD4+ and CD8+ T cells derived from peripheral blood of untreated multiple sclerosis (MS) patients with either relapsing-remitting (RR), secondary progressive (SP) or primary progressive (PP) MS and healthy controls (HC). Background: MS is an immune-mediated disease and cytokines have been hypothesized to contribute significantly to disease progression. Compared to the relapse-onset (RR, SP) form of the disease, PPMS patients have different clinical, immunological and pathological features. Surprisingly, the ability of their circulating T cells to produce immunoregulatory cytokines has not been extensively studied so far. Methods: Seventy-two MS patients (24 RR, 26 SP, 22 PP) and 34 HC were studied. Stimulated peripheral blood derived CD4+ and CD8+ T cells were analyzed for IFN-g, IL-2, TNF-a, IL-4, IL-10 and IL-13 production. Results: MS patients express significantly more CD4+ and CD8+ T cells producing IFN-g compared to HC. Compared to the other forms of the disease, PPMS patients display a significant decrease in CD4+ T cells producing IL-2, IL-13 and TNF-a and a significant increase in CD8+ T cells producing IL-4 and IL-10. Conclusions: The data presented here demonstrate that patients with PPMS express less pro- and more anti-inflammatory cytokine producing T cells compared to the relapse-onset form of the disease, confirming the view on PPMS as a distinct disease entity.

Key Words: T cells • cytokines • primary progressive MS

Multiple Sclerosis, Vol. 7, No. 3, 145-150 (2001)
DOI: 10.1177/135245850100700302


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Mult SclerHome page
A. Hebb, C. Moore, V Bhan, T Campbell, J. Fisk, H. Robertson, M Thorne, E Lacasse, M Holcik, J Gillard, et al.
Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination
Multiple Sclerosis, June 1, 2008; 14(5): 577 - 594.
[Abstract] [PDF]


Home page
Mult SclerHome page
M J Eikelenboom, J Killestein, B M. Uitdehaag, and C H Polman
Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis
Multiple Sclerosis, October 1, 2005; 11(5): 520 - 523.
[Abstract] [PDF]


Home page
Mult SclerHome page
M J Eikelenboom, J Killestein, B M. Uitdehaag, and C H Polman
Letter to the Editor
Multiple Sclerosis, June 1, 2004; 10(3): 334 - 335.
[PDF]


Home page
Mult SclerHome page
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis, June 1, 2004; 10(1_suppl): S23 - S30.
[Abstract] [PDF]


Home page
Mult SclerHome page
C. Lucchinetti and W. Bruck
The pathology of primary progressive multiple sclerosis
Multiple Sclerosis, May 1, 2004; 10(3_suppl): S23 - S30.
[Abstract] [PDF]


Home page
Mult SclerHome page
X Montalban and A J Thompson
Workshop on primary progressive multiple sclerosis: meeting summary
Multiple Sclerosis, April 1, 2002; 8(2): 177 - 178.
[PDF]


Home page
Mult SclerHome page
O. Neuhaus and H.-P. Hartung
In search of a disease marker: the cytokine profile of primary progressive multiple sclerosis
Multiple Sclerosis, June 1, 2001; 7(3): 143 - 144.
[PDF]



Advertisement